Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OnKure Therapeutics (OKUR)
NASDAQ:OKUR
Holding OKUR?
Track your performance easily
OKUR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.05 - $20.00
Previous CloseN/A
Volume8.61K
Average Volume (3M)165.36K
Market Cap
$71.62M
Enterprise ValueN/A
Total Cash (Recent Filing)$24.89M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.85
Shares Outstanding12,652,890
10 Day Avg. Volume173,229
30 Day Avg. Volume165,363
Standard Deviation0.29
R-Squared0.00238
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$34.20Price Target Upside547.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
OnKure Therapeutics News
PremiumCompany Announcements
OnKure Therapeutics Advances Cancer Drug Trials
PremiumCompany Announcements
OnKure Therapeutics Reports Strategic Merger and Financial Updates
Bulls Say, Bears Say
Bulls Say
Drug Development And EfficacyOnKure's OKI-219 shows promise as a third-generation PI3Kα inhibitor with higher selectivity for the H1047R mutant, potentially driving better efficacy and tolerability in cancer treatment.
Financial OutlookOnKure ended with $76.7M in cash, providing an operational runway into 2026, which positions the company to continue advancing its clinical programs.
Market PotentialOnKure's ~8-fold selectivity over its nearest competitor can provide a significant performance advantage in the billion-dollar PI3Kα inhibitor market.
Bears Say
Clinical TrialsNegative clinical results with the lead asset, OKI-219, pose significant risks to the stock's potential growth.
CompetitionCompetitive risks, especially with respect to other mutant-selective PI3Kα inhibitors, could undermine the company's market position.
Regulatory ApprovalsInability to obtain regulatory approvals in a timely manner or at all could hinder the company's progress and affect stock performance.
---
Ownership Overview
8.71% Insiders
0.12% Mutual Funds
0.03% Other Institutional Investors
89.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $5.05 and its highest was $20.00 in the past 12 months.
What is OnKure Therapeutics’s market cap?
OnKure Therapeutics’s market cap is $71.62M.
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is Mar 26, 2025 which is in 54 days.
How were OnKure Therapeutics’s earnings last quarter?
Currently, no data Available
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 12,652,890 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OnKure Therapeutics?
Currently, no hedge funds are holding shares in OKUR
---
OnKure Therapeutics Stock Smart Score
Company Description
OnKure Therapeutics
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
---
OKUR Stock 12 Month Forecast
Average Price Target
$34.20
▲(547.73% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Crispr Therapeutics AG
―
Allogene Therapeutics
―
Immatics
―
Best Analysts Covering OKUR
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
-17.03%
reiterated a sell rating 10 months ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -17.03% per trade.
---